Mechanism of long non-coding RNA GHET1 in tumors of the digestive system

Abstract

Ma Yingji, Sun Libin, Qiu Wensheng. Mechanism of long non-coding RNA GHET1 in tumors of the digestive system[J]. Journal of International Oncology, 2020, 47(5): 304-307.

References33

[1]	Espinosa JM. On the origin of lncRNAs: missing link found[J]. Trends Genet, 2017,33(10):660-662. DOI: 10.1016/j.tig.2017.07.005. doi:10.1016/j.tig.2017.07.005pmid:28778681
[2]	Jandura A, Krause HM. The new RNA world: growing evidence for long noncoding RNA functionality[J]. Trends Genet, 2017,33(10):665-676. DOI: 10.1016/j.tig.2017.08.002. doi:10.1016/j.tig.2017.08.002pmid:28870653
[3]	Tian X, Xu G. Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis[J]. BMJ Open, 2015,5(9):e008653. DOI: 10.1136/bmjopen-2015-008653. doi:10.1136/bmjopen-2015-008653pmid:26423854
[4]	Yu L, Chen S, Bao H, et al. The role of lncRNA CASC2 on prognosis of malignant tumors: a meta-analysis and bioinformatics[J]. Onco Targets Ther, 2018,11:4355-4365. DOI: 10.2147/OTT.S166132. doi:10.2147/OTT.S166132pmid:30100741
[5]	Yang F, Xue X, Zheng L, et al. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability[J]. FEBS J, 2014,281(3):802-813. DOI: 10.1111/febs.12625. doi:10.1111/febs.12625
[6]	Song J, Chen X, Tian Q, et al. The value of lncRNA GHET1 as a prognostic factor for survival of chinese cancer outcome: a meta-analysis[J]. Dis Markers, 2019,2019:5824190. DOI: 10.1155/2019/5824190. doi:10.1155/2019/5824190pmid:31885739
[7]	Ye J, Sun H, Feng Z, et al. Prognostic significance of lncRNA GHET1 expression in various cancers: a systematic review and meta-analysis[J]. Biosci Rep, 2019,39(10). pii: BSR20190608. DOI: 10.1042/BSR20190608.
[8]	Li C, Chen J, Zhang K, et al. Progress and prospects of long nonco-ding RNAs (lncRNAs) in hepatocellular carcinoma[J]. Cell Physiol Biochem, 2015,36(2):423-434. DOI: 10.1159/000430109. doi:10.1159/000430109pmid:25968300
[9]	蒋志俊, 陈洁, 黎乐群. 长链非编码RNA在肝癌侵袭转移中的研究进展[J]. 医学研究生学报, 2019,32(7):765-770. DOI: 10.16571/j.cnki.1008-8199.2019.07.019.
[10]	Ding G, Li W, Liu J, et al. LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma[J]. Biomed Pharmacother, 2017,94:326-331. DOI: 10.1016/j.biopha.2017.07.046. doi:10.1016/j.biopha.2017.07.046pmid:28772210
[11]	Wang Z, Luo S, Wan Z, et al. Glabridin arrests cell cycle and inhibits proliferation of hepatocellular carcinoma by suppressing braf/MEK signaling pathway[J]. Tumour Biol, 2016,37(5):5837-5846. DOI: 10.1007/s13277-015-4177-5. doi:10.1007/s13277-015-4177-5pmid:26586395
[12]	Jin L, He Y, Tang S, et al. LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2[J]. J Cell Physiol, 2018,233(6):4726-4734. DOI: 10.1002/jcp.26257. doi:10.1002/jcp.26257pmid:29139562
[13]	邹磊, 颉晚林, 张鑫, 等. LncRNA在胃癌早期诊断中的研究进展[J]. 国际检验医学杂志, 2019,40(1):102-107. DOI: 10.3969/j.issn.1673-4130.2019.01.027.
[14]	Lemm I, Ross J. Regulation of c-MYC mRNA decay by translational pausing in a coding region instability determinant[J]. Mol Cell Biol, 2002,22(12):3959-3969. DOI: 10.1128/MCB.22.12.3959-3969.2002. doi:10.1128/mcb.22.12.3959-3969.2002pmid:12024010
[15]	杜清, 杨巧红, 张新江, 等. c-myc在胃癌治疗方面的研究进展[J]. 转化医学电子杂志, 2018,5(9):53-58. DOI: 10.12095/j.issn.2095-6894.2018.09.011.
[16]	Xia Y, Yan Z, Wan Y, et al. Knockdown of long noncoding RNA GHET1 inhibits cell-cycle progression and invasion of gastric cancer cells[J]. Mol Med Rep, 2018,18(3):3375-3381. DOI: 10.3892/mmr.2018.9332. doi:10.3892/mmr.2018.9332pmid:30066922
[17]	Massague J. G₁cell-cycle control and cancer[J]. Nature, 2004,432(7015):298-306. DOI: 10.1038/nature03094. doi:10.1038/nature03094pmid:15549091
[18]	Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer[J]. Annu Rev Med, 1999,50(1):401-423. DOI: 10.1146/annurev.med.50.1.401. doi:10.1146/annurev.med.50.1.401
[19]	Donjerkovic D, Scott DW. Regulation of the G₁phase of the mammalian cell cycle[J]. Cell Res, 2000,10(1):1-16. DOI: 10.1038/sj.cr.7290031. doi:10.1038/sj.cr.7290031pmid:10765979
[20]	Zhang X, Bo P, Liu L, et al. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells[J]. Biomed Pharmacother, 2017,92:580-585. DOI: 10.1016/j.biopha.2017.04.111. doi:10.1016/j.biopha.2017.04.111pmid:28578256
[21]	Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017[J]. CA Cancer J Clin, 2017,67(3):177-193. DOI: 10.3322/caac.21395. doi:10.3322/caac.21395pmid:28248415
[22]	Tang X, Qiao X, Chen C, et al. Regulation mechanism of long noncoding RNAs in colon cancer development and progression[J]. Yonsei Med J, 2019,60(4):319-325. DOI: 10.3349/ymj.2019.60.4.319. doi:10.3349/ymj.2019.60.4.319pmid:30900417
[23]	利基林. 长链非编码RNA在结直肠癌中的研究进展[J]. 微创医学, 2018,13(6):766-768. DOI: 10.11864/j.issn.1673.2018.06.19.
[24]	Zhou J, Li X, Wu M, et al. Knockdown of long noncoding RNA GHET1 inhibits cell proliferation and invasion of colorectal cancer[J]. Oncol Res, 2016,23(6):303-309. DOI: 10.3727/096504016X14567549091305. doi:10.3727/096504016X14567549091305pmid:27131316
[25]	Findlay VJ, Wang C, Watson DK, et al. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer[J]. Cancer Gene Ther, 2014,21(5):181-187. DOI: 10.1038/cgt.2014.15. doi:10.1038/cgt.2014.15
[26]	Lim SH, Becker TM, Chua W, et al. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer[J]. J Clin Pathol, 2014,67(10):848-853. DOI: 10.1136/jclinpath-2014-202499. doi:10.1136/jclinpath-2014-202499
[27]	Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer[J]. Oncogene, 2013,32(13):1616-1625. DOI: 10.1038/onc.2012.193. doi:10.1038/onc.2012.193
[28]	Zhou HY, Zhu H, Wu XY, et al. Expression and clinical significance of long-non-coding RNA GHET1 in pancreatic cancer[J]. Eur Rev Med Pharmacol Sci, 2017,21(22):5081-5088. DOI: 10.26355/eurrev_201711_13822. doi:10.26355/eurrev_201711_13822pmid:29228419
[29]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338. doi:10.3322/caac.21338pmid:26808342
[30]	李晓敏, 邢瑶, 查文娟, 等. 长链非编码RNA在食管癌中作用的研究进展[J]. 山东医药, 2019,59(19):94-97. DOI: 10.396/j.issn.1002-266X.2019.19.027.
[31]	Liu H, Zhen Q, Fan Y. LncRNA GHET1 promotes esophageal squamous cell carcinoma cells proliferation and invasion via induction of EMT[J]. Int J Biol Markers, 2017,32(4):e403-e408. DOI: 10.5301/ijbm.5000304. doi:10.5301/ijbm.5000304pmid:28983895
[32]	Sasaki K, Natsugoe S, Ishigami S, et al. Significance of Twist expression and its association with E-cadherin in esophageal squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2009,28:158. DOI: 10.1186/1756-9966-28-158. doi:10.1186/1756-9966-28-158pmid:20025748
[33]	王国田, 张洋洋, 王志敏, 等. 上皮-间质转化在食管癌侵袭转移中的研究进展[J]. 医学综述, 2014,20(23):4280-4283. DOI: 10.3969/j.issn.1006-2084.014.23.022.

Mechanism of long non-coding RNA GHET1 in tumors of the digestive system

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References33

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Xu Kai, Wen Gang, Li Rui, Tian Yuan.Research progress on the prognostic value of the ratio of lymphocytes to C-reactive protein in digestive system neoplasms[J]. Journal of International Oncology, 2022, 49(10): 627-629.
[2]	Ju Xinyue, Hu Chunmei, Zhao Yue, Tang Yan.CDX2 and gastrointestinal neoplasms[J]. Journal of International Oncology, 2021, 48(6): 374-376.
[3]	Liu Peipei, Yang Mengxue, Yan Xuebing.Research advances of m⁶A methylation modification in digestive system neoplasms[J]. Journal of International Oncology, 2021, 48(11): 688-692.
[4]	Zhu Zemin, Xie Zhiqin, Sun Yongkang, Tang Caixi.MicroRNA-223 and digestive system tumors[J]. Journal of International Oncology, 2020, 47(2): 112-114.
[5]	Qi Ruili, Wang Huaqing.Research progress of tumor vascular targeting drugs combined with PD-1/PD-L1 antibody in the treatment of digestive system tumors[J]. Journal of International Oncology, 2019, 46(12): 750-754.
[6]	Zhou Shuaiyang, Gong Weijuan, Xiao Weiming.Mechanism of angiopoietinlike protein 4 in digestive system neoplasms[J]. Journal of International Oncology, 2018, 45(6): 371-374.
[7]	Shanshan, Zhou Yongning, Guan Quanlin.Long non-conding RNA TUG1 and digestive system cancers[J]. Journal of International Oncology, 2018, 45(11): 688-691.
[8]	Zhang Zijin, Ai Bin.Advances of immune checkpoint blockades in the treatment of digestive cancers[J]. Journal of International Oncology, 2017, 44(1): 63-66.
[9]	PAN Lei, LIANG Wei, FU Min, QIAN Hui, XU Wen-Rong, JIANG Peng-Cheng, ZHANG Xu.Long noncoding RNA in digestive system tumors[J]. Journal of International Oncology, 2016, 43(8): 706-710.
[10]	Zhao Jinlu, Li Guodong, Liu Ming.Mechanism of anticarcinogenic function of ellagic acid in gastrointestinal cancers[J]. Journal of International Oncology, 2016, 43(6): 472-474.
[11]	Wang Yan, Wang Lu, Feng Jiangzhou, Li Deng.Research progress of CTHRC1 in gastrointestinal cancers[J]. Journal of International Oncology, 2016, 43(5): 382-384.
[12]	Qiu Wangwang, Yang Zhili, Zheng Qi.Ring finger protein 43 gene and its function in digestive system cancer[J]. Journal of International Oncology, 2016, 43(1): 56-59.
[13]	CHEN Zheng, LIU Xiao-Feng, DONG Qian-Qian, MA Shu-Lin.Expression and role of miRNA375 in digestive system tumors[J]. Journal of International Oncology, 2015, 42(11): 863-865.
[14]	WANG Juan, HU Zhi-Qian.Research of hepatocyte nuclear factor 4α in digestive system tumors[J]. Journal of International Oncology, 2014, 41(12): 915-918.
[15]	LI Jing, QIAN Jun.Separation of digestive system cancer stem cell[J]. Journal of International Oncology, 2013, 40(3): 215-218.